PFE

Pfizer (PFE) Stock Rallies on November 21, 2025 as Investors Focus on FDA Win, Obesity Pivot and 7% Dividend Yield

New York – November 21, 2025 Pfizer (NYSE: PFE) finished Friday’s session on a strong note, with the stock climbing as investors digested a fresh U.S. FDA approval in bladder cancer, progress in obesity drugs, a multi‑billion‑dollar bond sale and

22 November 2025

Pfizer’s Q3 Shocker: Earnings Beat, Outlook Raised, and a $7 Billion Obesity Drug Gambit

Pfizer Stock Today (Nov. 18, 2025): PFE steadies near $25 as Pfizer launches multi‑tranche bond sale to help fund Metsera deal

Summary Live PFE snapshot (intraday) New today: Pfizer sells debt to fund Metsera Pfizer began marketing a U.S. dollar investment‑grade bond expected to raise at least $5 billion, with the deal structured in as many as seven parts. Early discussions

18 November 2025

Bond Sales · Mergers & Acquisitions · NASDAQ:BNTX · NYSE:PFE · Pfizer News · Pharmaceutical Industry · Stock Market

Pfizer (PFE) Clinches $10B Metsera Deal, Beating Novo Nordisk — What the Winning Bid Means for the Obesity-Drug Race (Nov. 8, 2025)

Pfizer (PFE) Stock: 9 Things to Know Before the Market Opens on November 17, 2025

New York — As U.S. markets get ready to reopen on Monday, November 17, 2025, Pfizer (NYSE: PFE) heads into the week at a critical turning point: COVID cash flows are fading, an obesity-drug arms race is heating up, a

16 November 2025

Financial Analysis · Investing · Market News · NYSE:PFE · Pharmaceuticals · Stocks